However, we observed that HS expression was more efficiently abrogated upon SLC35B2 knockout compared to EXT1 knockout in melanoma cells, along with a significantly more pronounced antiproliferative effect of the respective knockout cells in presence of Vemurafenib, suggesting a higher therapeutic potential of SLC35B2 compared to EXT1. The gene discussed is SLC35B2; the disease is melanoma.